Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy
Pharmaceuticals · 07.04.2026 · 19 (4) · 587
DOI: 10.3390/ph19040587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 07.04.2026. Verfasst von Maral Martin Mıldanoğlu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul 34083, Turkey. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Inflammatory and immune-based prognostic markers such as the Lung Immune Prognostic Index (LIPI) and the Glasgow Prognostic Score (GPS) have gained increasing attention in ES-SCLC, particularly in patients receiving first-line chemoimmunotherapy. However, no prior study has explored a broader, integrated inflammatory framework that evaluates these parameters collectively.
Methods
We retrospectively evaluated 166 patients with ES-SCLC treated with first-line platinum–etoposide plus atezolizumab or durvalumab between 2019 and 2025. LIPI could be calculated in 123 patients based on available dNLR and LDH values, while GPS and the Combined Inflammatory Prognostic Score (CIPS) could be assessed in 120 patients with accessible CRP and albumin data.
Results
Median PFS and OS were 8.16 and 15.96 months, respectively. In univariate analyses, poor ECOG PS, liver and bone metastases, poor LIPI, poor GPS, and high-risk CIPS were associated with shorter PFS and OS. In multivariate analysis, only LIPI and GPS remained independent predictors of both PFS and OS, while ECOG PS was independently associated with OS. Although CIPS demonstrated clear prognostic separation in univariate analysis, it did not retain independent significance, likely due to sample size limitations and overlap with LIPI and GPS components.
Conclusions
LIPI and GPS are strong independent prognostic markers in ES-SCLC receiving chemoimmunotherapy. While CIPS did not demonstrate independent prognostic value in multivariate analysis, its simplicity, balanced two-tier design, and use of routinely available biomarkers highlight its potential clinical utility. To our knowledge, this is the first study to assess a combined inflammatory prognostic model in this population. Prospective multicenter validation is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Medipol University, Istanbul 34083, Turkey.
- Department of Medical Oncology, Faculty of Medicine, Koc University, Istanbul 34460, Turkey.
ORCID-Profile: Maral Martin Mıldanoğlu, Fatih Kemik, Melisa Eryaşar, Erdem Sünger, Mehmet Haluk Yücel, Ebru Engin Delipoyraz, Sena Fidan, Harun Muğlu, Burçin Çakan Demirel, Jamshid Hamdard, Yasin Kutlu, Özgür Açıkgöz, Ahmet Bilici
Zitieren
APA
Mıldanoğlu, M. M., Kemik, F., Eryaşar, M., Özçelik, H., Sünger, E., Yücel, M. H., Engin Delipoyraz, E., Fidan, S., Muğlu, H., Çakan Demirel, B., Hamdard, J., Kutlu, Y., Açıkgöz, Ö., Selcukbiricik, F., Şeker, M., & Bilici, A. (2026). Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy. Pharmaceuticals, 19(4), 587. https://doi.org/10.3390/ph19040587
Vancouver
Mıldanoğlu MM, Kemik F, Eryaşar M, Özçelik H, Sünger E, Yücel MH, et al. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy. Pharmaceuticals. 2026;19(4):587. doi:10.3390/ph19040587
BibTeX
@article{Mldanolu2026,
author = {Mıldanoğlu, Maral Martin and Kemik, Fatih and Eryaşar, Melisa and Özçelik, Hakan and Sünger, Erdem and Yücel, Mehmet Haluk and Engin Delipoyraz, Ebru and Fidan, Sena and Muğlu, Harun and Çakan Demirel, Burçin and Hamdard, Jamshid and Kutlu, Yasin and Açıkgöz, Özgür and Selcukbiricik, Fatih and Şeker, Mesut and Bilici, Ahmet},
title = {Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {4},
pages = {587},
doi = {10.3390/ph19040587}
}
EUVIMED